These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 18384433)

  • 1. Vascular endothelial growth factor expression is closely related to irinotecan-mediated inhibition of tumor growth and angiogenesis in neuroblastoma xenografts.
    Kaneko S; Ishibashi M; Kaneko M
    Cancer Sci; 2008 Jun; 99(6):1209-17. PubMed ID: 18384433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged low-dose administration of the cyclooxygenase-2 inhibitor celecoxib enhances the antitumor activity of irinotecan against neuroblastoma xenografts.
    Kaneko M; Kaneko S; Suzuki K
    Cancer Sci; 2009 Nov; 100(11):2193-201. PubMed ID: 19673886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metronomic treatment of malignant glioma xenografts with irinotecan (CPT-11) inhibits angiogenesis and tumor growth.
    Takano S; Kamiyama H; Mashiko R; Osuka S; Ishikawa E; Matsumura A
    J Neurooncol; 2010 Sep; 99(2):177-85. PubMed ID: 20066473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced antitumor effect of lower-dose and longer-term CPT-11 treatment in combination with low-dose celecoxib against neuroblastoma xenografts.
    Kaneko S; Kaneko M; Fukushima T
    Int J Clin Oncol; 2013 Feb; 18(1):116-25. PubMed ID: 22127347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pleiotrophin, a candidate gene for poor tumor vasculature and in vivo neuroblastoma sensitivity to irinotecan.
    Calvet L; Geoerger B; Regairaz M; Opolon P; Machet L; Morizet J; Joseph JM; Elie N; Vassal G
    Oncogene; 2006 May; 25(22):3150-9. PubMed ID: 16501609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No topoisomerase I alteration in a neuroblastoma model with in vivo acquired resistance to irinotecan.
    Calvet L; Santos A; Valent A; Terrier-Lacombe MJ; Opolon P; Merlin JL; Aubert G; Morizet J; Schellens JH; Bénard J; Vassal G
    Br J Cancer; 2004 Sep; 91(6):1205-12. PubMed ID: 15292932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of systemic administration of irinotecan against neuroblastoma xenografts.
    Thompson J; Zamboni WC; Cheshire PJ; Lutz L; Luo X; Li Y; Houghton JA; Stewart CF; Houghton PJ
    Clin Cancer Res; 1997 Mar; 3(3):423-31. PubMed ID: 9815701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Balance of pro- versus anti-angiogenic splice isoforms of vascular endothelial growth factor as a regulator of neuroblastoma growth.
    Peiris-Pagès M; Harper SJ; Bates DO; Ramani P
    J Pathol; 2010 Oct; 222(2):138-47. PubMed ID: 20662003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of CPT-11 (a unique DNA topoisomerase I inhibitor) on a highly malignant xeno-transplanted neuroblastoma.
    Komuro H; Li P; Tsuchida Y; Yokomori K; Nakajima K; Aoyama T; Kaneko M; Kaneda N
    Med Pediatr Oncol; 1994; 23(6):487-92. PubMed ID: 7935175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PlGF and VEGF-A Regulate Growth of High-Risk MYCN-Single Copy Neuroblastoma Xenografts via Different Mechanisms.
    Zins K; Kovatchki D; Lucas T; Abraham D
    Int J Mol Sci; 2016 Sep; 17(10):. PubMed ID: 27669225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts.
    Vassal G; Terrier-Lacombe MJ; Bissery MC; Vénuat AM; Gyergyay F; Bénard J; Morizet J; Boland I; Ardouin P; Bressac-de-Paillerets B; Gouyette A
    Br J Cancer; 1996 Aug; 74(4):537-45. PubMed ID: 8761367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo treatment with CPT-11 leads to differentiation of neuroblastoma xenografts and topoisomerase I alterations.
    Santos A; Calvet L; Terrier-Lacombe MJ; Larsen A; Bénard J; Pondarré C; Aubert G; Morizet J; Lavelle F; Vassal G
    Cancer Res; 2004 May; 64(9):3223-9. PubMed ID: 15126363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metronomic administration of the drug GMX1777, a cellular NAD synthesis inhibitor, results in neuroblastoma regression and vessel maturation without inducing drug resistance.
    Fuchs D; Rodriguez A; Eriksson S; Christofferson R; Sundberg C; Azarbayjani F
    Int J Cancer; 2010 Jun; 126(12):2773-89. PubMed ID: 20112275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
    Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
    Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice.
    Takiguchi S; Kumazawa E; Shimazoe T; Tohgo A; Kono A
    Jpn J Cancer Res; 1997 Aug; 88(8):760-9. PubMed ID: 9330608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects.
    Sapra P; Kraft P; Pastorino F; Ribatti D; Dumble M; Mehlig M; Wang M; Ponzoni M; Greenberger LM; Horak ID
    Angiogenesis; 2011 Sep; 14(3):245-53. PubMed ID: 21452059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice.
    Allegrini G; Goulette FA; Darnowski JW; Calabresi P
    Cancer Chemother Pharmacol; 2004 Mar; 53(3):261-6. PubMed ID: 14658007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells.
    Koizumi F; Kanzawa F; Ueda Y; Koh Y; Tsukiyama S; Taguchi F; Tamura T; Saijo N; Nishio K
    Int J Cancer; 2004 Jan; 108(3):464-72. PubMed ID: 14648715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-145 inhibits the growth, invasion, metastasis and angiogenesis of neuroblastoma cells through targeting hypoxia-inducible factor 2 alpha.
    Zhang H; Pu J; Qi T; Qi M; Yang C; Li S; Huang K; Zheng L; Tong Q
    Oncogene; 2014 Jan; 33(3):387-97. PubMed ID: 23222716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoxia-inducible factor 1 upregulation of both VEGF and ANGPTL4 is required to promote the angiogenic phenotype in uveal melanoma.
    Hu K; Babapoor-Farrokhran S; Rodrigues M; Deshpande M; Puchner B; Kashiwabuchi F; Hassan SJ; Asnaghi L; Handa JT; Merbs S; Eberhart CG; Semenza GL; Montaner S; Sodhi A
    Oncotarget; 2016 Feb; 7(7):7816-28. PubMed ID: 26761211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.